Literature DB >> 24220144

SeqReporter: automating next-generation sequencing result interpretation and reporting workflow in a clinical laboratory.

Somak Roy1, Mary Beth Durso2, Abigail Wald2, Yuri E Nikiforov2, Marina N Nikiforova3.   

Abstract

A wide repertoire of bioinformatics applications exist for next-generation sequencing data analysis; however, certain requirements of the clinical molecular laboratory limit their use: i) comprehensive report generation, ii) compatibility with existing laboratory information systems and computer operating system, iii) knowledgebase development, iv) quality management, and v) data security. SeqReporter is a web-based application developed using ASP.NET framework version 4.0. The client-side was designed using HTML5, CSS3, and Javascript. The server-side processing (VB.NET) relied on interaction with a customized SQL server 2008 R2 database. Overall, 104 cases (1062 variant calls) were analyzed by SeqReporter. Each variant call was classified into one of five report levels: i) known clinical significance, ii) uncertain clinical significance, iii) pending pathologists' review, iv) synonymous and deep intronic, and v) platform and panel-specific sequence errors. SeqReporter correctly annotated and classified 99.9% (859 of 860) of sequence variants, including 68.7% synonymous single-nucleotide variants, 28.3% nonsynonymous single-nucleotide variants, 1.7% insertions, and 1.3% deletions. One variant of potential clinical significance was re-classified after pathologist review. Laboratory information system-compatible clinical reports were generated automatically. SeqReporter also facilitated quality management activities. SeqReporter is an example of a customized and well-designed informatics solution to optimize and automate the downstream analysis of clinical next-generation sequencing data. We propose it as a model that may envisage the development of a comprehensive clinical informatics solution.
Copyright © 2014 American Society for Investigative Pathology and the Association for Molecular Pathology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2013        PMID: 24220144     DOI: 10.1016/j.jmoldx.2013.08.005

Source DB:  PubMed          Journal:  J Mol Diagn        ISSN: 1525-1578            Impact factor:   5.568


  12 in total

1.  System for Informatics in the Molecular Pathology Laboratory: An Open-Source End-to-End Solution for Next-Generation Sequencing Clinical Data Management.

Authors:  Wenjun Kang; Sabah Kadri; Rutika Puranik; Michelle N Wurst; Sushant A Patil; Ibro Mujacic; Sonia Benhamed; Nifang Niu; Chao Jie Zhen; Bekim Ameti; Bradley C Long; Filipo Galbo; David Montes; Crystal Iracheta; Venessa L Gamboa; Daisy Lopez; Michael Yourshaw; Carolyn A Lawrence; Dara L Aisner; Carrie Fitzpatrick; Megan E McNerney; Y Lynn Wang; Jorge Andrade; Samuel L Volchenboum; Larissa V Furtado; Lauren L Ritterhouse; Jeremy P Segal
Journal:  J Mol Diagn       Date:  2018-04-24       Impact factor: 5.568

2.  Next-generation sequencing-based molecular characterization of primary urinary bladder adenocarcinoma.

Authors:  Somak Roy; Dinesh Pradhan; Wayne L Ernst; Stephanie Mercurio; Yana Najjar; Rahul Parikh; Anil V Parwani; Reetesh K Pai; Rajiv Dhir; Marina N Nikiforova
Journal:  Mod Pathol       Date:  2017-05-26       Impact factor: 7.842

3.  User-centered design of multi-gene sequencing panel reports for clinicians.

Authors:  Elizabeth Cutting; Meghan Banchero; Amber L Beitelshees; James J Cimino; Guilherme Del Fiol; Ayse P Gurses; Mark A Hoffman; Linda Jo Bone Jeng; Kensaku Kawamoto; Mark Kelemen; Harold Alan Pincus; Alan R Shuldiner; Marc S Williams; Toni I Pollin; Casey Lynnette Overby
Journal:  J Biomed Inform       Date:  2016-07-14       Impact factor: 6.317

Review 4.  Molecular approaches to thyroid cancer diagnosis.

Authors:  Susan J Hsiao; Yuri E Nikiforov
Journal:  Endocr Relat Cancer       Date:  2014-05-14       Impact factor: 5.678

5.  Subsets of salivary duct carcinoma defined by morphologic evidence of pleomorphic adenoma, PLAG1 or HMGA2 rearrangements, and common genetic alterations.

Authors:  Simion I Chiosea; Lester D R Thompson; Ilan Weinreb; Julie E Bauman; Alyssa M Mahaffey; Caitlyn Miller; Robert L Ferris; William E Gooding
Journal:  Cancer       Date:  2016-07-05       Impact factor: 6.860

Review 6.  GeneMed: An Informatics Hub for the Coordination of Next-Generation Sequencing Studies that Support Precision Oncology Clinical Trials.

Authors:  Yingdong Zhao; Eric C Polley; Ming-Chung Li; Chih-Jian Lih; Alida Palmisano; David J Sims; Lawrence V Rubinstein; Barbara A Conley; Alice P Chen; P Mickey Williams; Shivaani Kummar; James H Doroshow; Richard M Simon
Journal:  Cancer Inform       Date:  2015-03-19

7.  Identification of Driving ALK Fusion Genes and Genomic Landscape of Medullary Thyroid Cancer.

Authors:  Jun Ho Ji; Young Lyun Oh; Mineui Hong; Jae Won Yun; Hyun-Woo Lee; DeokGeun Kim; Yongick Ji; Duk-Hwan Kim; Woong-Yang Park; Hyun-Tae Shin; Kyoung-Mee Kim; Myung-Ju Ahn; Keunchil Park; Jong-Mu Sun
Journal:  PLoS Genet       Date:  2015-08-21       Impact factor: 5.917

Review 8.  Available resources and challenges for the clinical annotation of somatic variations.

Authors:  Catherine I Dumur
Journal:  Cancer Cytopathol       Date:  2014-08-08       Impact factor: 5.284

Review 9.  Molecular Signature of Indeterminate Thyroid Lesions: Current Methods to Improve Fine Needle Aspiration Cytology (FNAC) Diagnosis.

Authors:  Silvia Cantara; Carlotta Marzocchi; Tania Pilli; Sandro Cardinale; Raffaella Forleo; Maria Grazia Castagna; Furio Pacini
Journal:  Int J Mol Sci       Date:  2017-04-06       Impact factor: 5.923

10.  PathOS: a decision support system for reporting high throughput sequencing of cancers in clinical diagnostic laboratories.

Authors:  Kenneth D Doig; Andrew Fellowes; Anthony H Bell; Andrei Seleznev; David Ma; Jason Ellul; Jason Li; Maria A Doyle; Ella R Thompson; Amit Kumar; Luis Lara; Ravikiran Vedururu; Gareth Reid; Thomas Conway; Anthony T Papenfuss; Stephen B Fox
Journal:  Genome Med       Date:  2017-04-24       Impact factor: 11.117

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.